Listed

NEUROONE MEDICAL TECHNOLOGIES Corp: Form 10-Q for the period ended Jun 30, 2019

Filed with the SEC on Aug 14, 2019 and accepted by EDGAR at Aug 14, 2019, 20:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2019-04-01 to 2019-06-30$422.8kus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-10-01 to 2019-06-30$1.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-04-01 to 2019-06-30−$1.9mus-gaap:OperatingIncomeLoss
Operating income9 months2018-10-01 to 2019-06-30−$4.5mus-gaap:OperatingIncomeLoss
Net income3 months2019-04-01 to 2019-06-30−$1.9mus-gaap:NetIncomeLoss
Net income9 months2018-10-01 to 2019-06-30−$5.4mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-04-01 to 2019-06-30−$0.14us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-10-01 to 2019-06-30−$0.48us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-10-01 to 2019-06-30−$4.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-10-01 to 2019-06-30$54.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2019-06-30$1.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-06-30$1.3mus-gaap:AssetsCurrent
Total assetsAt period end2019-06-30$1.5mus-gaap:Assets
Current liabilitiesAt period end2019-06-30$1.8mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-06-30$1.8mus-gaap:Liabilities
Shareholders' equityAt period end2019-06-30−$273.4kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001213900-19-015795. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.